0001209191-18-050957.txt : 20180913 0001209191-18-050957.hdr.sgml : 20180913 20180913184806 ACCESSION NUMBER: 0001209191-18-050957 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180911 FILED AS OF DATE: 20180913 DATE AS OF CHANGE: 20180913 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cole G Bradley CENTRAL INDEX KEY: 0001337798 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-51541 FILM NUMBER: 181069825 MAIL ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: GENOMIC HEALTH INC CENTRAL INDEX KEY: 0001131324 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 770552594 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-556-9300 MAIL ADDRESS: STREET 1: 301 PENOBSCOT DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-09-11 0 0001131324 GENOMIC HEALTH INC GHDX 0001337798 Cole G Bradley 301 PENOBSCOT DRIVE REDWOOD CITY CA 94063 0 1 0 0 COO Common Stock 2018-09-11 4 M 0 5000 17.18 A 50372 D Common Stock 2018-09-11 4 S 0 3400 63.8661 D 46972 D Common Stock 2018-09-11 4 S 0 1600 64.3306 D 45372 D Employee Stock Option (right to buy) 17.18 2018-09-11 4 M 0 5000 0.00 D 2020-02-18 Common Stock 5000 51471 D Includes an aggregate of 16,534 shares of common stock issuable pursuant to previously reported restricted stock units that have not vested. These sales of common stock were effected pursuant to Rule 10b5-1 sales plan adopted by the reporting person on June 4, 2018. Reporting person undertakes to provide upon request by the Securities and Exchange Commission, the issuer or a securityholder of the issuer detailed information regarding the price and number of shares sold within the range indicated. Represents weighted average sale price. Actual sale prices ranged from $63.21 to $64.19. Represents weighted average sale price. Actual sale prices ranged from $64.21 to $64.52. The option became exercisable as to 25% of the shares on February 18, 2011, and became exercisable as to 1/48th of the shares each full month thereafter. /s/ Jason W. Radford, Attorney-in-fact 2018-09-13